Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
On univariate analysis, frailty was significantly associated with age (p < 0.001), smoking history (p = 0.020), heart failure (p < 0.001), T2DM (p < 0.001), COPD (p < 0.001), chronic renal failure (p < 0.001), active cancer (p = 0.002), BMI (p < 0.001), median red cell vitamin B1 (p < 0.001), median red cell vitamin B2 (p = 0.013), median red cell selenium (p = 0.004), median plasma selenium (p < 0.001), low plasma selenium (p < 0.001), median serum magnesium (p < 0.001), low serum magnesium (p < 0.001), median serum LDH (p < 0.001), serum LDH (p = 0.001), median serum albumin (p < 0.001), serum albumin (p < 0.001) and thirty-day mortality (p < 0.001).The relationship between frailty status and clinicopatholgical characteristics, BMI, MUST, micronutrient level, systemic inflammatory response and clinical outcomes in patients with COVID-19 (n = 281)Not frail (CFS ≤ 3, n = 143)Frail (CFS > 3, n = 138)P1 valueAge (years)< 0.001 < 70104 (73%)22 (16%) ≥ 7039 (27%)116 (84%)Sex0.113 Male94 (66%)78 (56%) Female49 (34%)60 (44%)Smoking Hx0.02 Never99 (69%)77 (56%) Ex/current44 (31%)61 (44%)Alcohol excess Hx0.481 No131 (92%)123 (89%) Yes12 (8%)15 (11%)Hypertension0.211 No77 (54%)64 (46%) Yes66 (46%)74 (54%)Heart failure< 0.001 No130 (91%)105 (76%) Yes13 (9%)33 (24%)T2DM< 0.001 No113 (79%)81 (59%) Yes30 (21%)57 (41%)COPD< 0.001 No133 (93%)105 (76%) Yes10 (7%)33 (24%)Chronic renal failure< 0.001 No128 (89%)90 (65%) Yes15 (11%)48 (35%)Liver disease0.13 No133 (93%)121 (88%) Yes10 (7%)17 (12%)Active cancer0.002 No136 (95%)116 (84%) Yes7 (5%)22 (16%)BMI (kg/m2, n = 229)< 0.001 < 2527 (23%)59 (53%) ≥ 2590 (77%)53 (47%)MUST (n = 255)0.071 Low114 (88%)101 (80%) Medium: high risk15 (12%)25 (20%)Median red cell vitamin B1 (ng/g Hb, n = 194)304 (243 to 389)362 (277 to 490)< 0.001Low red cell vitamin B1 (ng/g Hb, n = 194)0.071 No68 (64%)67 (76%) Yes38 (36%)21 (24%)Median red cell vitamin B2 (nmol/g of Hb, n = 64)1.93 (1.70 to 2.12)2.32 (1.90 to 2.78)0.013Low red cell vitamin B2 (nmol/g of Hb, n = 64)1 No36 (100%)28 (100%) Yes0 (0%)0 (0%)Median red cell vitamin B6 (pmol/g of Hb, n = 64)443 (362 to 549)478 (352 to 608)0.771Low red cell vitamin B6 (pmol/g of Hb, n = 64)0.188 No36 (100%)26 (93%) Yes0 (0%)2 (7%)Median red cell selenium (nmol/g Hb, n = 198)5.84 (5.02 to 6.93)5.44 (4.65 to 6.04)0.004Low red cell selenium (nmol/g Hb, n = 198)1 No108 (100%)90 (100%) Yes0 (0%)0 (%)Median plasma selenium (µmol/L, n = 262)0.86 (0.59 to 1.00)0.66 (0.54 to 0.84)< 0.001Low plasma selenium (µmol/L, n = 262)< 0.001 No78 (59%)41 (31%) Yes54 (41%)89 (69%)Median serum vitamin B12 (ng/L, n = 262)496 (297 to 862)448 (290 to 790)0.307Low serum vitamin B12 (ng/L, n = 262)1 No126 (96%)125 (95%) Yes5 (4%)6 (5%)Median serum vitamin D (nmol/L, n = 111)32 (19 to 62)27 (16 to 77)0.813Low serum vitamin D (nmol/L, n = 111)0.427 No15 (33%)26 (40%) Yes31 (67%)39 (60%)Median serum magnesium (mmol/L, n = 264)0.83 (0.77 to 0.90)0.78 (0.70 to 0.85)< 0.001Low serum magnesium (mmol/L, n = 264)< 0.001 No109 (83%)85 (64%) Yes23 (17%)47 (36%)Median plasma copper (µmol/L, n = 262)20 (16 to 24)20 (17 to 23)0.391High plasma copper (µmol/L, n = 262)0.226 No82 (62%)90 (69%) Yes50 (38%)40 (31%)Median (IQR) serum LDH (U/L, n = 264)234 (177 to 341)193 (160 to 252)< 0.001Serum LDH (U/L, n = 264)0.001 ≤ 24068 (51%)42 (32%) > 24064 (49%)90 (68%)Median (IQR) serum CRP (mg/L)69 (24 to 146)51 (17 to 109)0.072Serum CRP (mg/L)0.05 ≤ 1016 (11%)23 (17%) Nov-8061 (43%)66 (48%) > 8066 (46%)49 (35%)Median (IQR) serum albumin (g/L)33 (30 to 37)31 (27 to 34)< 0.001Serum albumin (g/L)< 0.001 ≥ 3561 (43%)31 (23%) < 3582 (57%)107 (77%)Oxygen requirement0.093 No97 (68%)106 (77%) Yes46 (32%)32 (23%)ITU admission0.187 No126 (88%)128 (93%) Yes17 (12%)10 (7%)30-day mortality< 0.001 No125 (87%)79 (57%) Yes18 (13%)59 (43%)Significant p values are shown in bold1p value is from χ2 analysis or Fisher’s exact test when value of single cell n ≤ 5 for categorical variables and Mann: Whitney U test for continuous variables
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were classified as no risk (MUST = 0), or at risk of malnutrition (MUST ≥ 1).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted to hospital with COVID-19
Study design awaiting verification · Journal of Translational Medicine · 2023
Original publication title
The relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted to hospital with COVID-19
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Micronutrients have been associated with disease severity and poorer clinical outcomes in patients with COVID-19. However, there is a paucity of studies examining if the relationship with micronutrient status and clinical outcomes is independent of recognised prognostic factors, specifically frailty and the systemic inflammatory response (SIR). The aim of the present study was to examine the relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted with COVID-19.
Source: BackgroundAbstract: What methods does the paper describe?
Retrospective analysis of prospectively collected data was performed on patients with confirmed COVID-19, admitted to hospital between the 1st April 2020 to 6th July 2020. Clinicopathological characteristics, frailty assessment, biochemical and micronutrient laboratory results were recorded. Frailty status was determined using the Clinical Frailty scale. SIR was determined using serum CRP. Clinical outcomes of interest were oxygen requirement, ITU admission and 30-day mortality. Categorical variables were analysed using chi-square test and binary logistics regression analysis. Continuous variables were analysed using the Mann: Whitney U or Kruskal Wallis tests.
Source: MethodsAbstract: Results
281 patients were included. 55% (n = 155) were aged ≥ 70 years and 39% (n = 109) were male. 49% (n = 138) of patients were frail (CFS > 3). 86% (n = 242) of patients had a serum CRP > 10 mg/L. On univariate analysis, frailty was significantly associated with thirty-day mortality (p < 0.001). On univariate analysis, serum CRP was found to be significantly associated with an oxygen requirement on admission in non-frail patients (p = 0.004).
Over a third (36%) of non-frail patients had a low vitamin B1, despite having normal reference range values of red cell B2, B6 and selenium. Furthermore, serum CRP was found to be significantly associated with a lower median red cell vitamin B1 (p = 0.029).
Source: ResultsAbstract: Conclusion
Vitamin B1 stores may be depleted in COVID-19 patients experiencing a significant SIR and providing rationale for thiamine supplementation. Further longitudinal studies are warranted to delineate the trend in thiamine status following COVID-19.
Source: ConclusionAuthors’ abstract
Background
Micronutrients have been associated with disease severity and poorer clinical outcomes in patients with COVID-19. However, there is a paucity of studies examining if the relationship with micronutrient status and clinical outcomes is independent of recognised prognostic factors, specifically frailty and the systemic inflammatory response (SIR). The aim of the present study was to examine the relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted with COVID-19.
Methods
Retrospective analysis of prospectively collected data was performed on patients with confirmed COVID-19, admitted to hospital between the 1st April 2020 to 6th July 2020. Clinicopathological characteristics, frailty assessment, biochemical and micronutrient laboratory results were recorded. Frailty status was determined using the Clinical Frailty scale. SIR was determined using serum CRP. Clinical outcomes of interest were oxygen requirement, ITU admission and 30-day mortality. Categorical variables were analysed using chi-square test and binary logistics regression analysis. Continuous variables were analysed using the Mann: Whitney U or Kruskal Wallis tests.
Results
281 patients were included. 55% (n = 155) were aged ≥ 70 years and 39% (n = 109) were male. 49% (n = 138) of patients were frail (CFS > 3). 86% (n = 242) of patients had a serum CRP > 10 mg/L. On univariate analysis, frailty was significantly associated with thirty-day mortality (p < 0.001). On univariate analysis, serum CRP was found to be significantly associated with an oxygen requirement on admission in non-frail patients (p = 0.004).
Over a third (36%) of non-frail patients had a low vitamin B1, despite having normal reference range values of red cell B2, B6 and selenium. Furthermore, serum CRP was found to be significantly associated with a lower median red cell vitamin B1 (p = 0.029).
Conclusion
Vitamin B1 stores may be depleted in COVID-19 patients experiencing a significant SIR and providing rationale for thiamine supplementation. Further longitudinal studies are warranted to delineate the trend in thiamine status following COVID-19.
Publication and source details
Original title: The relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted to hospital with COVID-19
Josh McGovern; John Wadsworth; Anthony Catchpole; Conor Richards; Donald C. McMillan; Tadhg Kelliher; Emma Goodall; Ellie Murray; Terry Melaugh; Shannon McPhillips; Kathryn Brice; Katie Barbour; Sophie Robinson; Peter Moffitt; Olivia Kemp; Dinesh Talwar; Donogh Maguire
Journal of Translational Medicine · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T19:32:46.033974+00:00
DOI: 10.1186/s12967-023-04138-y · PMC10139911